Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US

Co-Founder

Executive Vice President & CFO

Executive Vice President and Chief Commercial Officer

Senior Vice President,Global Government Strategy, Market Access and Value

Vertex Pharmaceuticals has an office in Boston

Boston, US (HQ)

50 Northern Ave

Vertex Pharmaceuticals's revenue was reported to be $1.7 b in FY, 2016 which is a **65% increase** from the previous period.

## Revenue (FY, 2016) | $1.7 b |

## Revenue growth (FY, 2015 - FY, 2016), % | 65% |

## Net income (FY, 2016) | ($84 m) |

## EBIT (FY, 2016) | $9.9 m |

## Market capitalization (19-May-2017) | $29.4 b |

## Closing share price (19-May-2017) | $117.9 |

## Cash (31-Dec-2016) | $1.2 b |

Vertex Pharmaceuticals's current market capitalization is $29.4 b.

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Revenue | $1.2 b | $580.4 m | $1 b | $1.7 b |

## Revenue growth, % | (52%) | 78% | 65% | |

## Operating expense total | $2.1 b | $1.3 b | $1.5 b | $1.7 b |

## EBIT | ($903.4 m) | ($692.4 m) | ($466.9 m) | $9.9 m |

## EBIT margin, % | (75%) | (119%) | (45%) | 1% |

## Interest expense | $22.7 m | $72.9 m | $84.2 m | $81.4 m |

## Interest income | $22.7 m | |||

## Pre tax profit | ($976.1 m) | |||

## Income tax expense | ($288.6 m) | $7 m | $30.4 m | $16.7 m |

## Net Income | ($687.6 m) | ($742.7 m) | ($588.2 m) | ($84 m) |

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Cash | $569.3 m | $625.3 m | $714.8 m | $1.2 b |

## Accounts Receivable | $85.5 m | $76 m | $177.6 m | $201.1 m |

## Inventories | $14.1 m | $30.8 m | $57.2 m | $77.6 m |

## Current Assets | $1.6 b | $1.5 b | $1.4 b | $1.8 b |

## PP&E | $696.9 m | $715.8 m | $697.7 m | $698.4 m |

## Goodwill | $31 m | $39.9 m | $50.4 m | $50.4 m |

## Total Assets | $2.3 b | $2.3 b | $2.5 b | $2.9 b |

## Accounts Payable | $49.3 m | $71.2 m | $74.9 m | $61.5 m |

## Current Liabilities | $397.8 m | $368.3 m | $506.3 m | $792.5 m |

## Additional Paid-in Capital | $5.3 b | $5.8 b | $6.2 b | $6.5 b |

## Retained Earnings | ($4 b) | ($4.7 b) | ($5.3 b) | ($5.4 b) |

## Total Equity | $1.1 b | $1.3 b | ||

## Financial Leverage | 2.3 x | 2.2 x |

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Net Income | ($687.6 m) | ($742.7 m) | ($588.2 m) | ($84 m) |

## Depreciation and Amortization | $48.4 m | $63.3 m | $62.3 m | $61.4 m |

## Accounts Receivable | $53.4 m | $7.4 m | ($100 m) | ($33 m) |

## Inventories | $7.1 m | ($16 m) | ($23 m) | ($16 m) |

## Accounts Payable | ($49.2 m) | $25 m | ($1.7 m) | ($11.7 m) |

## Cash From Operating Activities | ($51.6 m) | ($513.2 m) | ($365.4 m) | |

## Cash From Investing Activities | ($54.1 m) | $74 m | $268.9 m | $104.5 m |

## Cash From Financing Activities | $180.9 m | $497.4 m | $188.9 m | $133.3 m |

## Interest Paid | $11 m | $8.7 m | $85.6 m | $83.7 m |

## Income Taxes Paid | $2.8 m | $1.2 m | $1.8 m |

Y, 2016 | |
---|---|

## Revenue/Employee | $830.3 k |

## Financial Leverage | 2.2 x |